Your browser doesn't support javascript.
loading
Prognosis after surgery for gastric adenocarcinoma in the Swedish Gastric Cancer Surgery Study (SWEGASS).
Asplund, Johannes; Gottlieb-Vedi, Eivind; Leijonmarck, Wilhelm; Mattsson, Fredrik; Lagergren, Jesper.
Afiliação
  • Asplund J; Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Gottlieb-Vedi E; Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Leijonmarck W; Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Mattsson F; Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Lagergren J; Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Acta Oncol ; 60(4): 513-520, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33502275
ABSTRACT

BACKGROUND:

Most studies examining prognostic factors after gastrectomy come from selected patients and non-Western populations. This nationwide population-based cohort study aims to identify prognostic factors after surgery for gastric adenocarcinoma in an unselected Western cohort.

METHODS:

This study included 98% of patients who underwent gastrectomy for gastric adenocarcinoma in Sweden in 2006-2015, with follow-up through 2019. Data were collected from medical records and national registries. Exposures were sex, age, education, comorbidity, tumor sub-localization, tumor stage, calendar period, and pre-operative chemotherapy. Outcomes were 3-year all-cause and disease-specific mortality. Cox regression produced hazard ratios (HRs) with 95% confidence intervals (95% CIs), adjusted for the other study exposures.

RESULTS:

Among all 2154 patients, 3-year all-cause mortality was 53.3%. Factors influencing 3-year all-cause mortality after multivariable adjustment were tumor stage (stage IV vs. stage 0-I HR 8.72, 95% CI 6.77-11.24), comorbidity (Charlson comorbidity score ≥2 vs. 0 HR 1.63, 95% CI 1.39-1.90), age (>75 vs. <65 years HR 1.48, 95% CI 1.24-1.78), and calendar period (2006-2010 vs. 2011-2015 HR 0.83, 95% CI 0.73-0.95). No independent prognostic influence was found for sex (women vs. men HR 1.01, 95% CI 0.85-1.09), pre-operative chemotherapy (yes vs. no HR 0.92, 95% CI 0.78-1.08), tumor sub-localization (non-cardia vs. cardia HR 1.01, 95% CI 0.83-1.22), or education (≥13 vs. ≤9 years HR 0.89, 95% CI 0.74-1.07). The results were similar for 3-year disease-specific mortality.

CONCLUSION:

Survival after gastrectomy for gastric adenocarcinoma needs further improvement. Tumor stage, comorbidity, age, and calendar period were independently prognostic, while sex, pre-operative chemotherapy, tumor sub-localization, and education were not.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article